Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by increasing demand for effective pain management solutions, including medications, therapies, and medical devices. This trend encourages investment in research and development to meet the growing need for diverse, sustainable treatment options.
New York, USA, Jan. 30, 2025 (GLOBE NEWSWIRE) — Chronic Pain Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain
Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by increasing demand for effective pain management solutions, including medications, therapies, and medical devices. This trend encourages investment in research and development to meet the growing need for diverse, sustainable treatment options.
DelveInsight’s ‘Chronic Pain Pipeline Insight 2025‘ report provides comprehensive global coverage of pipeline chronic pain therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the chronic pain pipeline domain.
Key Takeaways from the Chronic Pain Pipeline Report
- DelveInsight’s chronic pain pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline chronic pain drugs.
- Key chronic pain companies such as Apurano Pharmaceuticals, Centrexion Therapeutics, Neumentum Inc., Grünenthal, Synerkine Pharma, Intra-Cellular Therapies Inc., Mesoblast, ANANDA Scientific Inc., and others are evaluating new chronic pain drugs to improve the treatment landscape.
- Promising pipeline chronic pain therapies such as Adezunap (AP707), CNTX-6970, NTM-006, CNTX 0290, (NOP), SK-01, ITI-333, Rexlemestrocel-L, Nantheia, and others are under different phases of chronic pain clinical trials.
- In January 2025, Tris Pharma, Inc. announced positive topline results from its ALLEVIATE-1 pivotal Phase III clinical trial evaluating cebranopadol, an investigational therapy, for the treatment of moderate-to-severe acute pain in patients following abdominoplasty surgery. These results add to the growing body of data underscoring the promising efficacy and safety profile of cebranopadol, a first-in-class pain therapy involving dual-nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor (dual-NMR) agonism.
- In October 2024, ANANDA Scientific Inc., a research-focused biopharmaceutical company announced the commencement of a clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD), leveraging ANANDA’s proprietary delivery technology, co-administered with delta-9-tetrahydrocannabinol (THC), for its potential efficacy in treating co-occurring opioid use disorder (OUD) and chronic pain.
- In July 2024, Mesoblast announced that it had begun subject enrolment in Phase III clinical trial of rexlemestrocel-L for patients with chronic low back pain (CLBP) caused by inflammatory degenerative disc disease. Rexlemestrocel-L is an allogeneic, immunoselected, and industrially produced stromal cell product.
- In February 2023, Mesoblast’s rexlemestrocel-L, an investigational allogeneic human bone marrow-derived mesenchymal precursor cell (MPC) therapy, received regenerative medicine advanced therapy (RMAT) designation from the FDA’s Office of Tissues and Advanced Therapies for the treatment of chronic low back pain (CLBP) associated with disc degeneration in combination with hyaluronic acid (HA).
Request a sample and discover the recent advances in chronic pain drugs @ Chronic Pain Pipeline Report
The chronic pain pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage chronic pain drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the chronic pain clinical trial landscape.
Chronic Pain Overview
Pain originates from receptor nerve cells beneath the skin and in various organs throughout the body. When the body experiences illness, injury, or other issues, these receptor cells transmit signals along nerve pathways to the spinal cord, which then sends the message to the brain. Pain medications work by reducing or blocking these signals before they reach the brain. Chronic pain is one of the most expensive health problems in the U.S., contributing to increased medical costs, lost wages, decreased productivity, compensation claims, and legal expenses. For example, low back pain is a significant health issue and a common cause of restricted activity in adults, while cancer pain affects many individuals with advanced cancer.
Chronic pain can have many causes. It may begin after an illness or injury from which a person has long since recovered, but the pain persists. In some cases, ongoing conditions like arthritis or cancer are the source of the pain. Some people experience chronic pain without any prior injury or illness. It can manifest in various forms across the body, with common types including arthritis, back and neck pain, cancer pain near a tumor, migraines, testicular pain, and persistent pain in scar tissue.
The mechanisms of pain involve acute or chronic processes triggered by peripheral stimuli, which lead to the sensation of pain. Biologists understand pain as a warning sign of potential tissue damage, serving a protective function. However, in some cases, pain may arise due to disruptions in the nociceptive process, either at the peripheral or central level or due to psychological factors. Identifying abnormal pain states is crucial in distinguishing them from instances of actual tissue damage. Chronic pain is defined as lasting for more than 3 to 6 months.
Healthcare providers may conduct a physical examination and order tests to determine the cause of pain. These may include blood tests, electromyography to assess muscle activity, imaging tests like X-rays and MRIs, nerve conduction studies to evaluate nerve function, reflex and balance tests, spinal fluid analysis, and urine tests.
Chronic pain impacts every aspect of life, and the most effective treatment focuses on symptom relief and support. A comprehensive, multidisciplinary approach is often necessary for managing pain. Treatment may include over-the-counter medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or acetaminophen, along with prescription painkillers like opioids for more severe pain. However, prescription opioids are generally reserved for serious cases due to their potential for misuse and serious side effects.
Find out more about chronic pain drugs @ Chronic Pain Analysis
A snapshot of the Pipeline Chronic Pain Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Adezunap (AP707) | Apurano Pharmaceuticals GmbH | III | Cannabinoid receptor CB1 agonists | Sublingual spray |
| CNTX-6970 | Centrexion Therapeutics | II | CCR2 receptor antagonists | Oral |
| NTM-006 | Neumentum | II | Adenosine A3 receptor modulators | Oral |
| CNTX 0290 | Centrexion Therapeutics | II | Somatostatin receptor subtype 4 agonists | Oral |
Learn more about the emerging chronic pain therapies @ Chronic Pain Clinical Trials
Chronic Pain Therapeutics Assessment
The chronic pain pipeline report proffers an integral view of the emerging chronic pain therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.
Scope of the Chronic Pain Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intravenous, Subcutaneous, Oral, Intramuscular
- Therapeutics Assessment By Molecule Type: Monoclonal antibody, Small molecule, Peptide
- Therapeutics Assessment By Mechanism of Action: Cannabinoid receptor CB1 agonists, CCR2 receptor antagonists, Adenosine A3 receptor modulators, Somatostatin receptor subtype 4 agonists
- Key Chronic Pain Companies: Apurano Pharmaceuticals, Centrexion Therapeutics, Neumentum Inc., Grünenthal, Synerkine Pharma, Intra-Cellular Therapies Inc., Mesoblast, ANANDA Scientific Inc., and others.
- Key Chronic Pain Pipeline Therapies: Adezunap (AP707), CNTX-6970, NTM-006, CNTX 0290, (NOP), SK-01, ITI-333, Rexlemestrocel-L, Nantheia, and others.
Dive deep into rich insights for new chronic pain treatments, visit @ Chronic Pain Drugs
Table of Contents
| 1. | Chronic Pain Pipeline Report Introduction |
| 2. | Chronic Pain Pipeline Report Executive Summary |
| 3. | Chronic Pain Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Chronic Pain Clinical Trial Therapeutics |
| 6. | Chronic Pain Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Chronic Pain Pipeline: Late-Stage Products (Phase III) |
| 8. | Chronic Pain Pipeline: Mid-Stage Products (Phase II) |
| 9. | Chronic Pain Pipeline: Early-Stage Products (Phase I) |
| 10. | Chronic Pain Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Chronic Pain Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Chronic Pain Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the chronic pain pipeline therapeutics, reach out @ Chronic Pain Therapeutics
Related Reports
Chronic Pain Epidemiology Forecast
Chronic Pain Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted chronic pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic pain companies, including AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Inc., Pfizer, Anika Therapeutics, Inc., Biogen, Tonix Pharmaceuticals, Inc., Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical Gmbh, among others.
Chronic Lower Back Pain Market
Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CLBP companies, including Eli Lilly and Company, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, among others.
Chronic Lower Back Pain Pipeline
Chronic Lower Back Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lower back pain companies, including Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, among others.
Chronic Back Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic back pain companies, including Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Consulting Services
Healthcare Conference Coverage
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com
